Integer Holdings Corporation Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Integer Holdings Corporation (ITGR).

If you purchased or acquired Integer Holdings securities between October 2024 and October 22, 2025, and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Integer Holdings

Integer Holdings Corporation is a medical device manufacturer specializing in advanced technologies for the cardiac, vascular, and neuromodulation markets.

Integer Holdings has expanded its footprint through acquisitions and investments in new product lines, including electrophysiology and neuromodulation products.

Potential Concerns Under Investigation

Lawyers are investigating whether Integer Holdings may have made misleading statements or omitted material facts regarding the performance, adoption, and demand for its new product launches between October 2024 and October 22, 2025.

During this time, Integer Holdings issued a series of upbeat forecasts emphasizing strong growth in its electrophysiology and neuromodulation businesses. For example, in its third-quarter 2024 earnings release on October 24, 2024, management highlighted “continued strong performance” and raised 2024 guidance to project 10% to 11% sales growth.

The company reiterated these optimistic projections in early 2025, citing “new product ramps” and “strong growth in emerging neuromodulation customers” as primary drivers.

Throughout the year the company allegedly continued to assure investors of “high visibility to customer demand.” On July 24, 2025, after reporting second-quarter results, Integer’s stock fell 5% pre-market even as management raised profit guidance, with the CFO asserting that the company was “maintaining its sales guidance.”

Lawyers are reviewing whether investors were fully informed of any early signs of weakening demand before the October guidance reduction.

In its October 23, 2025 press release, Integer Holdings updated its 2025 outlook and provided preliminary outlooks for 2026 and 2027. On the earnings call the same day, management said recent customer updates would create a 3 to 4% headwind to 2026 sales from three new products, two electrophysiology and one neuromodulation, due to slower adoption.

On this news, the stock fell 32.28% closing to closing, from $109.11 on October 22, 2025 to $73.89 on October 23, 2025, causing significant harm to investors.

Your Rights and Next Steps

This is an investigation, not a filed lawsuit. Investors who purchased or otherwise acquired Integer Holdings securities between October 2024 and October 22, 2025, and suffered financial losses may have legal rights. Lawyers are ready to help investors understand whether they may be eligible to participate in any future class action that could arise from this investigation.

If the investigation uncovers evidence of misleading statements, omissions, or other potential securities law violations, a class action lawsuit may be filed on behalf of affected investors. By joining the investigation, investors can help ensure their interests are represented and that they are kept informed about any developments or opportunities to recover losses.

It is important for investors to act promptly, as securities investigations and potential class actions are subject to strict deadlines. Investors who act now can preserve their rights and maximize their chances of recovery if a lawsuit is filed.

You May Be Entitled to Compensation

If you purchased Integer Holdings securities during the relevant period and suffered losses, you may be eligible to join any potential class action and seek compensation. Securities investigations are time-sensitive, so it is important to act quickly.

To participate in the investigation and protect your rights, complete the form below.